Compare Rambus Inc. Common Stock (RMBS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rambus Inc. Common Stock vs Zoetis Inc — how do they compare? Rambus Inc. Common Stock trades at $88.22 (market cap $9.99B), while Zoetis Inc trades at $75.98 (market cap $31.11B). The key difference: Zoetis Inc is far larger — about 3.1× Rambus Inc. Common Stock's market cap, and Zoetis Inc pays a 2.82% dividend while Rambus Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rambus Inc. Common Stock for 0 Days and Zoetis Inc for 71 Days on average.
| RMBS | ZTS | |
|---|---|---|
Market Cap | $9.99B | $31.11B |
Volume | 1,884,427 | 2,515,954 |
Sector | Technology | Health |
52-Week High | $170.66 | $147.53 |
52-Week Low | $79.73 | $69.09 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $9.19B | $38.68B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Zoetis (ZTS) trades at $74.30, down 1.78% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with 27.69% net income margin and 64.91% ROE, though recent Q1 2026 earnings missed expectations. Revenue growth has been steady, reaching $9.47B in 2025, while analyst consensus price target sits at $87.33 with 46.88% buy ratings. Recent news highlights competitive pressures in the U.S. companion animal market but acknowledges the company's industry-leading margins.
ZTS presents a compelling value opportunity with a P/E of 12.12 below sector averages, supported by robust cash flow generation and dividend payments. Near-term risks include U.S. market weakness and competitive pressures, but long-term growth drivers in international and livestock segments provide upside potential. The stock's current valuation reflects these headwinds, creating potential for appreciation as business conditions stabilize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
